Skip to main content
. 2017 Feb 19;2017:9591319. doi: 10.1155/2017/9591319

Table 1.

Characteristics of the studies included in the meta-analysis.

Study ID (first author, year) Classification of GERD Type of syndrome Sample size Age (years) Course of disease Duration Intervention Outcome measures
EG (M/F) CG (M/F) EG CG
He and Han 2016 [29] NERD Stagnated heat in liver and stomach syndrome 45 (26/19) 45 (29/16) 21–68 2 days–102 days 8 weeks Modified Banxia Xiexin
decoction, 100 mL, b.i.d
PPIs ①④⑤
Shou 2015 [30] N/A N/A 43 (24/19) 43 (23/20) E: 51.7 ± 12.9  
C: 52.6 ± 12.9
1 year–10 years 60 d Banxia Xiexin
decoction, 100 mL, t.i.d
PPIs + 5-HT4RA ①⑥
Yang et al. 2015 [31] RE N/A 70 (38/32) 69 (35/34) E: 41.89 ± 5.67  
C: 40.31 ± 6.98
E: 4.56 ± 1.23  
C: 4.09 ± 1.68
3 months Modified Banxia Xiexin
decoction plus Sini Powder, b.i.d
PPIs + D2RA ②③⑥
Wang et al. 2013 [32] N/A Cold and heat mixed type 56 (30/26) 56 (32/24) 22–64 1 year–12 years 8 weeks Modified Banxia Xiexin
decoction, b.i.d + point injection (vitamin B6), q.o.d
PPIs + D2RA ①②⑦
Chen 2013 [33] N/A Stagnation of liver and stomach Qi, stomachache due to cold, deficiency of stomach, yin, hyperactivity of stomach, heat, syndrome of retention of food in stomach E:C 58/58
M:F 70/46
21–68 0.5 year–13 years 4 weeks Modified Banxia Xiexin
decoction, b.i.d
PPIs + 5-HT4RA ①⑥
Sun et al. 2013 [34] N/A N/A 30 (17/13) 30 (14/16) 21–61 1 year–6 years 30 d Modified Banxia Xiexin
decoction
PPIs + D2RA ①②⑥⑧
Cao 2013 [35] RE N/A 32 (26/6) 32 (22/10) Mentioned N/A 8 weeks Modified Banxia Xiexin
decoction, 1 dose/d
D2RA + H2RA ①②⑥
Zhu et al. 2012 [36] RE N/A 60 (32/28) 60 (29/31) 19–72 3 months–12 years 4 weeks Banxia Xiexin decoction plus Xuanfu Daizhe decoction, 250 mL, b.i.d PPIs ①⑥
Shen 2012 [37] RE Cold and heat mixed type 43 (27/16) 40 (26/14) 26–70 N/A 56 days Modified Banxia Xiexin decoction, 100 mL, b.i.d PPIs + D2RA ①⑨
Lu et al. 2010 [38] RE Stomach Qi rising 39 (20/19) 39 (19/20) 20–65 1–6 years 4 weeks Modified Banxia Xiexin decoction, b.i.d PPIs + 5-HT4RA ①②⑥
Chen et al. 2009 [39] RE N/A 90 (56/34) 60 (39/21) 18–69 2–10 weeks 8 months Modified Banxia Xiexin decoction, 150 mL, b.i.d PPIs ①②③⑥⑨
Huang and Wu 2007 [40] RE N/A 60 (35/25) 60 (38/22) 18–61 2 months–30 years 8 weeks Modified Banxia Xiexin decoction, b.i.d PPIs + 5-HT4RA

①: overall clinical efficacy; ②: efficacy under gastroscope; ③: recurrence rate; ④: RDQ, SAS, and SDS grading; ⑤: SF-36 dimensions of grading; ⑥: symptom integrals; ⑦: plasma GAS level; ⑧: pathological effect; ⑨: RE classification in gastroscopy; GERD: gastroesophageal reflux disease; NERD: nonerosive reflux disease; RE: reflux esophagitis; M: male; F: female; EG: experiment group; CG: control group; N/A: not applicable; RDQ: reflux disease diagnostic questionnaire; SAS: self-rating anxiety scale; SDS: self-rating depression scale; PPIs: proton pump inhibitors; 5-HT4RA: 5-HT4 receptor agonists; D2RA: D2 receptor antagonists; H2RA: H2 receptor antagonists.